Forecasts of Consolidated Financial Results for FY2025
Released on November 4, 2025 (Revised)
| Millions of yen |
FY2024 Actual |
FY2025 Previous Forecast |
FY2025 Revised Forecast |
YOY Actual |
YOY % |
| Net Sales |
64,139 |
75,000 |
71,000 |
6,860 |
10.7% |
| Operating profit |
5,331 |
6,800 |
6,000 |
668 |
12.5% |
| Ordinary profit |
5,107 |
6,800 |
6,000 |
892 |
17.5% |
| Profit attributable to owners of parent |
5,101 |
5,200 |
5,000 |
△101 |
△2.0% |
Overview of Earnings Forecast (announced on February 2, 2026)
In addition to contributions from overseas business, R&D expenses for the fourth quarter are expected to be in line with the plan, and full-year sales and profit are expected to increase.
Note. R&D expenses increased in 4Q FY2024 due to temporary factors. There have been no changes to the FY2025 forecast announced on November 4, 2025.
Overview of Earnings Forecast (announced on November 4, 2025)
Regarding the sales transactions of imported products procured from outside Vietnam and sold domestically by the Company’s Vietnamese subsidiary, Ha Tay Pharmaceutical Joint Stock Company (hereinafter, “Hataphar”), the consolidated statement of income for the first quarter of FY2025 recorded the total amount as net sales. However, after reviewing the above transaction, the Company determined that Hataphar does not control the goods or services to be transferred to the customer and that the transaction falls under the category of an "agent" that provides only the service of arranging these goods or services.
In accordance with the Group's accounting policies, the Company has therefore decided to amend its sales recording method to a net basis, whereby the amount paid to suppliers is deducted from the amount received from customers. Consequently, the forecasted net sales have been revised downward from the previously announced figure.
With regard to profits, the Company has revised its forecasts for operating profit ordinary income, and net income attributable to owners of parent to be lower than previously announced due to various factors such as an expected increase in R&D expenses resulting from the active promotion of R&D investments aimed at expanding the pipeline for future growth and strengthening drug discovery capabilities.
There will be no change to dividends in line with the forecast revision. The Company's policy is to maintain stable dividends while returning profits in line with business performance.
(NOTE) The above forecasts have been prepared based on information available as of the announcement date and are subject to various uncertainties. As a result, actual results may differ from this forecast.